Brought to you by 
Nitto Denko partners siRNA fibrosis candidates with BMS
16 Feb 2017
Executive Summary
Bristol-Myers Squibb Co. received an exclusive global license to develop, manufacture, and sell Nitto Denko Corp.'s siRNA candidates developed using vitamin A-coupled lipid nanoparticle delivery technology. The deal includes lead Phase Ib program NDL02s0201, a heat shock protein 47 (HSP47) antagonist for advanced liver fibrosis due to nonalcoholic steatohepatitis (NASH) or hepatitis C virus (HCV).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Liposomes
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nitto Denko partners siRNA fibrosis candidates with BMS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice